Obstetric hemorrhage

Current Opinion in Anaesthesiology

Volumn 28, Issue 2, 2015, Pages 186-190

  Van De Velde, Marc ^a   Diez, Christian ^b   Varon, Albert J ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

cell salvage; fibrinogen; hemorrhage; obstetric; peripartum hysterectomy; postpartum; tranexamic acid; transfusion; uterine atony

Indexed keywords

FIBRINOGEN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

ARTERY CATHETERIZATION; ARTIFICIAL EMBOLISM; CLINICAL PROTOCOL; HUMAN; INTRAUTERINE BALLOON; MATERNAL MORBIDITY; MATERNAL MORTALITY; OBSTETRIC HEMORRHAGE; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL; REVIEW; TEAMWORK; UTERINE TAMPONADE; FEMALE; PREGNANCY;

ANTIFIBRINOLYTIC AGENTS; FEMALE; HUMANS; POSTPARTUM HEMORRHAGE; PREGNANCY;

EID: 84926391844     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0000000000000168     Document Type: Review

References (29)

1. Bonnet MP, Basso O, Bouvier-Colle MH, et al. Postpartum hemorrhage in Canada and France: a population based comparison. PLoS One 2013; 8: e66882.
2. Centre for Maternal and Child Enquiries (CMACE). Saving Mothers' Lives: reviewing maternal deaths to make motherhood safer: 2006-08. The Eighth Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011; 118(Suppl. 1): 1-203.
3. Montefar-Rueda C, Rodriguez L, Jarquin JD, et al. Severe postpartum hemorrhage from uterine atony: a multicentric study. J Pregnancy 2013; 2013: 525914.
4. Kramer MS, Berg C, Abenhaim H, et al. Incidence, risk factors, and temporal trends in severe postpartum hemorrhage. Am J Obstet Gynecol 2013; 209: 449.e1-449.e7.
5. Bateman BT, Berman MF, Riley LE, et al. The epidemiology of postpartum hemorrhage in a large, nationwide sample of deliveries. Anesth Analg 2010; 110: 1368-1373.
6. Vercauteren M, Palit S, Soetens F, et al. Anaesthesiological considerations on tocolytic and uterotonic therapy in obstetrics. Acta Anaesthesiol Scand 2009; 53: 701-709.
7. Archer TL, Knape K, Liles D, et al. The hemodynamics of oxytocin and other vasoactive agents during neuraxial anesthesia for cesarean delivery: findings in six cases. IJOA 2008; 17: 247-254.
8. Jonsson M, Hanson U, Lidell C, et al. ST depression at caesarean section and the relation to oxytocin dose. A randomised controlled trial. BJOG 2010; 117: 76-83.
9. Thomas JS, Koh SH, Cooper GM. Haemodynamic effects of oxytocin given as IV bolus or infusion on women undergoing caesarean section. Brit J Anaesth 2007; 98: 116-119.
10. Zhao Y, Zhang Y, Li Z. Appropriate second-line therapies for management of severe postpartum hemorrahge. Int J Gynecol Obstet 2014; 127: 180-182.
11. Chai VYK, To WW. Uterine compression sutures for management of severe postpartum hemorrhage: a five-year audit. Hong Kong Med J 2014; 20: 113-120.
12. Kong MC, To WW. Balloon tamponade for postpartum haemorrhage: case series and literature review. Hong Kong Med J 2013; 19: 484-490.
13. Parazzini F, Ricci E, Cipriani S, et al. Temporal trends and determinants of peripartum hysterectomy in Lombardy, Northern Italy, 1996-2010. Arch Obstet Gynecol 2013; 287: 223-228.
14. Gronvall M, Tikkanen M, Metsätähti M, et al. Pelvic arterial embolisation in severe obstetric hemorrhage. Acta Obstet Gynecol Scand 2014; 93: 716-719.
15. Hwang SM, Jeon GS, Kim MD, et al. Transcatheter arterial embolisation for the management of obstetric hemorrhage associated with placental abnormality. Eur Radiol 2013; 23: 766-773.
16. Gerli S, Favilli A, Affronti G, et al. Prophylactic arterial catheterisation in the management of high risk patients for obstetric hemorrhage. Eur Rev Med Pharmacol Sci 2013; 17: 2822-2826.
17. Minas V, Gul N, Shaw E, Mwenenchanya S. Prophylactic balloon occlusion of the common iliac arteries for the managemzent of suspected placenta accreta/percreta: conclusions from a short case series. Arch Gynecol Obstet 2015; 291: 461-465.
18. Bonnet MP, Basso O. Prohemostatic interventions in obstetric hemorrhage. Semin Thromb Hemost 2012; 38: 259-264.
19. Ahonen J. The role of recombinant activated factor VII in obstetric hemorrhage. Curr Opinion Anesthesiol 2012; 25: 309-314.
20. Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thrombosis Haemostasis 2007; 5: 266-273.
21. Bell SF, Rayment R, Collins PW, Collis RE. The use of fibrinogen concentrate to correct hypofibrinogenemia rapidly during obstetric hemorrhage. Int J Obstet Anesth 2010; 19: 218-234.
22. Kikuchi M, Itakura A, Miki A, et al. Fibrinogen concentrate substitution therapy for obstetric hemorrhage complicated by coagulopathy. J Obstet Gynaecol Res 2013; 39: 770-776.
23. Ahmed S, Harrity C, Johnson S, et al. The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric hemorrhage: an observational study. Transfus Med 2012; 22: 344-349.
24. Nedeff N, Hakala P. Anesthetic Management of the Pregnant Trauma Patient. In: Varon AJ, Smith CE, editors. Essentials of trauma anesthesia. Cambridge: Cambridge University Press; 2012. pp. 288-298.
25. Kacmar R, Mhyre JM, Scavone BM, et al. The use of postpartum hemorrhage protocols in United States academic obstetric anesthesia units. Anesth Analg 2014; 119: 906-910.
26. Girard T, Manfred M, Schlembach D. New approaches to obstetric hemorrhage: the postpartum hemorrhage consensus algorithm. Curr Opin Anaesthesiol 2014; 27: 267-274.
27. Shields LE, Wiesner S, Fulton J, et al. Comprehensive maternal hemorrhage protocols reduce the use of blood products and improve patient safety. Am J Obstet Gynecol 2014. [Epub ahead of print]. doi: 10.1016/j.ajog. 2014.07.012.
28. Dutton RP, Lee LA, Stephens LS, et al. Massive hemorrhage: a report from the anesthesia closed claims project. Anesthesiology 2014; 121: 450-458.
29. Scavone BM, Tung A. The transfusion dilemma: more, less, or more organized? Anesthesiology 2014; 121: 439-441.